A randomized, double-blind trial in 300 patients has shown that 900 μg subcutaneous pasireotide is more effective than placebo for preventing pancreatic fistula after pancreatic resection. The regimens began on the morning of the operation and continued for 7 days. Fistula occurred less often in patients who received pasireotide than in the placebo group (9% versus 21%), suggesting that perioperative treatment with pasireotide can reduce the incidence of postoperative pancreatic fistula.